Navigation Links
Michael A. Marletta Takes Office as New President of Scripps Research Institute
Date:1/2/2012

LA JOLLA, Calif., Jan. 2, 2012 /PRNewswire/ -- Renowned biochemist Michael A. Marletta, PhD, assumed the post of president and CEO of The Scripps Research Institute January 1, succeeding Richard A. Lerner, MD, who led the institution for more than two decades.

(Photo:  http://photos.prnewswire.com/prnh/20120102/DC28698 )

"I'm excited by the opportunity to advance the institute's mission, creating knowledge in the biosciences and applying that knowledge to understanding and curing human disease," said Marletta. "I also look forward to working with all the dynamic, committed people who make the institute's work possible."

Marletta moved to Scripps Research from the University of California, Berkeley, where he served as chair of the Department of Chemistry, co-director of the Chemical Biology Graduate Program, Aldo DeBenedictis Distinguished Professor of Chemistry, and Professor of Biochemistry in the Department of Molecular and Cell Biology. He joined the Scripps Research faculty July 1, 2011, following his selection by the Board of Trustees as the institute's next head.

A former recipient of the prestigious MacArthur Fellowship as well as many other awards and honors, Marletta has focused his laboratory research on the intersection of chemistry and biology. He is an acknowledged pioneer in discovering the role of nitric oxide, a critical player in communication between cells.

Marletta is the third head of the institute in the 50 years since it began its focus on basic biomedical research. Its first director was Frank Dixon, MD, who arrived with his colleagues at the Scripps Clinic and Research Foundation (a forerunner of The Scripps Research Institute) in 1961 and was appointed head of research operations in 1970. Lerner, who had led the institute since 1987, will remain a member of the Scripps Research faculty.

For more information on Marletta, see his Scripps Research faculty web page at http://www.scripps.edu/research/faculty/marletta

About The Scripps Research Institute

The Scripps Research Institute is one of the world's largest independent, non-profit biomedical research organizations. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neuroscience, and vaccine development, as well as for its insights into autoimmune, cardiovascular, and infectious disease. Headquartered in La Jolla, California, the institute also includes a campus in Jupiter, Florida, where scientists focus on drug discovery and technology development in addition to basic biomedical science. Scripps Research currently employs about 3,000 scientists, staff, postdoctoral fellows, and graduate students on its two campuses. The institute's graduate program, which awards PhD degrees in biology and chemistry, is ranked among the top ten such programs in the nation. For more information, see www.scripps.edu


'/>"/>
SOURCE Scripps Research Institute
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Michael Cusumano, MITs Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors
2. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
3. NeuroCog Trials Appoints Industry Executive Michael Hufford, Ph.D. to Chief Operating Officer
4. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
5. Netsmart Technologies Names Michael Valentine as Chief Executive Officer
6. BioNeutral Appoints Michael D. Francis, J.D. as Director to the Board
7. Michael J. Fox Foundation Awards Grant to Zymes LLC
8. Dr. Michael Hanley Joins Celtaxsys as CEO
9. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of a New Dermal Patch for Parkinsons Disease
10. Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO
11. Michael J. Fox Foundation Launches Parkinsons Progression Markers Initiative (PPMI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A ... offer a new way to treat the disease. Surviving Mesothelioma has just posted an ... Scientists from several Korean institutions based their mesothelioma study on the fact the Manumycin ...
(Date:5/19/2016)... , ... May 19, 2016 , ... Anton Paar USA, ... square foot office building is complete. The new structure adds a third office building ... Anton Paar USA purchased 2.4 acres of land, along with office space adjacent ...
(Date:5/19/2016)... NEW YORK , May 19, 2016 ... Biotech space will fully recover given the relentless pressures ... is for sure in the investors circle though - ... requires due-diligence. Ahead of today,s session, ActiveWallSt.com,s presents four ... PTLA ), Vitae Pharmaceuticals Inc. (NASDAQ: ...
(Date:5/19/2016)... , May 19, 2016 ... and (OTC PINK: RGBPP) announced today initiation of ... first cord blood based cancer immunotherapeutic product leveraging ... application, Regen described a generation of cord blood ... by gene silencing.  The product in development will ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):